Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Sales (2016 - 2025)

ImmunityBio (IBRX) has disclosed Return on Sales for 12 consecutive years, with 1.62% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 622.0% to 1.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3.1% through Dec 2025, up 2495.0% year-over-year, with the annual reading at 3.1% for FY2025, 2495.0% up from the prior year.
  • Return on Sales for Q4 2025 was 1.62% at ImmunityBio, up from 2.1% in the prior quarter.
  • The five-year high for Return on Sales was 1.62% in Q4 2025, with the low at 7357.0% in Q1 2022.
  • Average Return on Sales over 5 years is 1248.45%, with a median of 451.42% recorded in 2021.
  • The sharpest move saw Return on Sales plummeted -677800bps in 2022, then skyrocketed 703316bps in 2023.
  • Over 5 years, Return on Sales stood at 234.75% in 2021, then crashed by -532bps to 1483.92% in 2022, then decreased by -13bps to 1679.24% in 2023, then skyrocketed by 100bps to 7.84% in 2024, then skyrocketed by 79bps to 1.62% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 1.62%, 2.1%, and 3.5% for Q4 2025, Q3 2025, and Q2 2025 respectively.